Etarfolatide and vintafolide are currently being evaluated in the phase III PROCEED trial (platinum resistant ovarian cancer) and the phase IIb TARGET trial in non-small cell lung cancer (:NSCLC) patients, respectively. Endocyte completed enrollment in the phase IIb TARGET study with top-line data from the study expected in the first quarter of 2014. In the first half of 2014, Endocyte expects to complete enrollment in the phase III PROCEED study. This deal brings together Endocyte's different approach to personalized medicine and Nihon Medi-Physics' single-photon emission computed tomography (:SPECT) imaging in Japan. Endocyte carries a Zacks Rank #4 (Sell). Stocks that currently look attractive include Biogen Idec Inc. ( BIIB ), Gilead Sciences Inc. ( GILD ) and Affymetrix Inc. ( AFFX ).